Structure Therapeutics (NASDAQ:GPCR) Given “Overweight” Rating at Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a research report issued on Monday, Benzinga reports. They currently have a $65.00 target price on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 47.66% from the company’s previous close.

A number of other research firms have also recently weighed in on GPCR. BMO Capital Markets increased their price objective on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, June 7th. Morgan Stanley began coverage on shares of Structure Therapeutics in a report on Monday. They set an “overweight” rating and a $118.00 target price on the stock. Finally, JMP Securities reduced their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $88.33.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $44.02 on Monday. The stock has a market capitalization of $2.05 billion, a P/E ratio of -57.17 and a beta of -3.52. The company has a 50 day moving average price of $37.91 and a 200 day moving average price of $39.71. Structure Therapeutics has a fifty-two week low of $26.61 and a fifty-two week high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. Research analysts forecast that Structure Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Sandia Investment Management LP acquired a new stake in shares of Structure Therapeutics in the 2nd quarter valued at $39,000. Quarry LP acquired a new stake in shares of Structure Therapeutics in the 2nd quarter valued at $79,000. Sectoral Asset Management Inc. acquired a new stake in shares of Structure Therapeutics in the 4th quarter valued at $139,000. ADAR1 Capital Management LLC acquired a new stake in shares of Structure Therapeutics in the 4th quarter valued at $163,000. Finally, Sei Investments Co. acquired a new stake in shares of Structure Therapeutics in the 2nd quarter valued at $212,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.